GlassScriptPhysician profile
Jennifer L Mclaughlin
NPI 1174726186
$6,025.66
in general payments reported to CMS, 2019-2025
31 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $927 · 2022: $473 · 2023: $989 · 2024: $1,411 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,113 · Travel and Lodging: $488 · Consulting Fee: $24.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,112.80 |
| Travel and Lodging | $487.56 |
| Consulting Fee | $24.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,194.09 | 2021-2025 | Onyx Frontier, Aurora Ev-Icd Mri Surescan |
| Janssen Pharmaceuticals, INC | $619.16 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $563.06 | 2021-2025 | |
| Boston Scientific Corporation | $456.89 | 2024-2025 | Watchman Access System, Farapulse |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $434.37 | 2023-2025 | Lifevest |
| Amgen INC. | $373.65 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $350.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $321.53 | 2021-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $201.12 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $175.85 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.97 | 2021-2025 | Jardiance |
| Biosense Webster, INC. | $146.28 | 2025 | Carto 3 |
| Edwards Lifesciences Corporation | $137.87 | 2025 | |
| Organogenesis INC. | $134.44 | 2025 | Puraply Wound Matrix |
| Baxter Healthcare | $85.62 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $85.25 | 2022 | |
| Esperion Therapeutics, INC. | $75.07 | 2021 | |
| Bridgebio Pharma, INC. | $73.58 | 2025 | Attruby |
| Heartflow, INC. | $72.19 | 2021-2024 | Ffrct |
| Abiomed | $55.48 | 2024 | Impella |
| Amarin Pharma, INC. | $52.42 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $46.34 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $43.81 | 2025 | |
| Sanofi-Aventis U.S. LLC | $40.08 | 2024 | |
| Kestra Medical Technology Services, INC. | $22.27 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $21.61 | 2024 | Arcalyst |
| Ossur Americas, INC. | $20.60 | 2025 | |
| Atricure, INC. | $18.35 | 2025 | Epi-Ease Epicardial Access System, Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax |
| Bardy Diagnostics, INC. | $18.00 | 2022 | |
| Daiichi Sankyo INC. | $17.49 | 2023 | Injectafer |
| Scpharmaceuticals INC. | $15.75 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.